The global health community is concerned that tuberculosis (TB) continues to disproportionately kill people living with HIV, despite the availability of TB preventive therapy. According to the World Health Organization’s Global Tuberculosis Report 2019, deaths attributed to TB among people living with HIV account for 17 percent of all TB deaths, even though people living with HIV account for only 8.6 percent of overall TB cases.
At recent global health meetings that assessed progress made against the HIV epidemic, presentation after presentation confirmed that the world is inching closer to epidemic control. The excitement at these gatherings was palpable. It would be the first time in human history that such a public health milestone would be achieved without either a cure or a vaccine.
As technical experts attending these meetings, we were struck by the critical importance of logistical and operational interventions, alongside biomedical ones, to reach the last mile. Yet, unlike the private sector, public health systems in low- and middle-income countries often remain underfunded and understaffed. This environment can make project management very challenging.
The Determined, Resilient, Empowered, AIDS-free, Mentored and Safe women (DREAMS) partnership aspires to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. These countries alone accounted for more than half of the HIV infections that occurred among adolescent girls and young women globally in 2015.
DREAMS reaches beyond the health sector to address the direct and indirect factors that increase girls’ HIV risk, such as poverty, gender inequality, sexual violence and inadequate education. Interventions can include paying school fees, providing bicycles to girls who would otherwise walk long distances to school, supplying sanitary napkins for menstrual hygiene management and offering mentoring to help girls avoid early pregnancy, gender-based violence and discrimination. DREAMS is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), the Bill & Melinda Gates Foundation, Girl Effect, Johnson & Johnson, Gilead Sciences and ViiV Healthcare.
Two young women who participate in DREAMS projects attended FHI 360’s 2018 Gender 360 Summit and discussed how DREAMS is making a difference in their lives. Here are their stories.
The focus of the global effort to end the HIV/AIDS epidemic, now 37 years on, is epidemic control, which the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) defines as limiting the annual number of new HIV infections in a country to less than the number of deaths among people living with HIV.
Sub-Saharan Africa, home to 26 million (70 percent) of the global total of 36.9 million people living with HIV, is where the battle must be won. To succeed and sustain the gains achieved in the past 15 years, countries in Africa will need to assume greater responsibility for managing their epidemics.
A version of this post originally appeared on FHI 360’s R&E Search for Evidence blog.
Known around the world, Prof. Peter Lamptey is a global health champion in any light. Many of you may know him from his early involvement in the global HIV response or from his fight to raise public awareness of noncommunicable diseases (NCDs). I first heard Prof. Lamptey speak about the role of laboratory science in the NCD response at a conference plenary hosted by the African Society for Laboratory Medicine, my former employer. A compelling talk for sure, but notably his plenary was also my first significant introduction to FHI 360’s research.
Every year, the International AIDS Society (IAS) holds the largest open scientific conference on HIV and AIDS-related issues. This year’s conference, IAS 2017, will take place in July in Paris. FHI 360 is a media partner with IAS 2017, and in the lead-up to this year’s conference, we are coordinating Facebook Live conversations with experts who will be speaking there.
One U.S. expert who will present at the conference is Dr. Anthony Fauci, Director of the U.S. National Institute of Allergy and Infectious Diseases. Dr. Fauci was recently in Washington, DC, to speak at the annual meeting of the HIV Prevention Trials Network. After his plenary talk, Dr. Fauci sat down with FHI 360’s Dr. Otto Chabikuli, Director of Global Health, Population and Nutrition, for a Facebook Live chat on the science of HIV. Dr. Fauci talked about his experience working in HIV research for more than 35 years, addressing issues such as what a cure for HIV might look like, the multiple ways to prevent HIV infection, treatment as prevention, and the projects that his team is currently working on.